GSK Investigational Site

East Melbourne, Victoria 3002

0 studies enrolling now · 10 studies all time

What they study most

Cancer, Carcinoma, Renal Cell, Herpes Zoster, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms, Breast

Studies at this site

• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma — Completed
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies — Completed
• A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor — Stopped early
• Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A — Completed
• Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma — Completed
• A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer — Completed
• GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma — Completed
• Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma — Completed
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed
• Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor — Completed